Agios Pharmaceuticals Inc (AGIO) Company Profile & Statistics

Agios Pharmaceuticals Inc
AGIO
(Nasdaq - US)
Closed
55.54
+0.92 (+1.68%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
54.64
High
56.19
Low
53.87

About Agios Pharmaceuticals Inc

CEO

Brian Goff

Headquarters

88 sidney street

cambridge, ma 02139, united states

Auditor

PricewaterhouseCoopers LLP

Employees

386

Share Holders

Website

www.agios.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

Agios Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	3.17B
Enterprise Value	2.91B
Enterprise Value/EBITDA (ttm)	-7.10
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.91
Price to Sales (ttm)	94.40
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	89.50%
Operating Margin (ttm)	-85.51%
Profit Margin (ttm)	1778.11%
Return on Equity (ttm)	-2.93%
Return on Invested Capital (ttm)	20.93%
Return on Assets (ttm)	-2.58%

Income Statement

Revenue (ttm)	32.87M
Revenue Per Share (ttm)	0.58
Gross Profit (ttm)	29.38M
EBITDA (ttm)³	-410.55M
Net Income Avi to Common (ttm)	674.31M
Diluted EPS (ttm)	11.36

Share Statistics

Beta (5Y Monthly)	0.75
52-Week Change	158.33%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	57.03M
Dividend Yield	0.00%
Float ⁴	54.22M
% Held by Insiders	4.93%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	1.00B
Total Cash Per Share (mrq)	17.62
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	8.99%
Quick Ratio (mrq)	8.77%
Book Value Per Share (mrq)	28.53

Cash Flow

Operating Cash Flow Per Share (ytd)	-4.39
Free Cash Flow (ytd)	-257.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Agios Pharmaceuticals Inc

Trade With A Regulated Broker